To investigate whether ultrasound-guided percutaneous portal vein catheterization can be successfully carried out in the intrahepatic region of patients with unliquefied bacterial liver abscess (UBLA), who are subsequently treated with an injection of antibiotics.
INTRODUCTION
A BACTERIAL LIVER abscessoccurs when multiple microorganisms invade the liver, resulting in the formation of several lesions; these lesions are identified in several images obtained using sophisticated diagnostic techniques. 1 In terms of clinical symptoms, most patients suffer from fever and chills. 2 According to previous publications, this condition has a high mortality rate, which varies from 6.5% to 31%. [2] [3] [4] [5] [6] Patients diagnosed in the final stage of this serious infectious disease usually develop septicemia and septic shock. If this condition is left untreated, it eventually leads to death. Therefore, appropriate and effective treatments must be provided immediately to improve the survival rate of such patients.
Conventionally, patients with bacterial liver abscess are subjected to the following modes of treatment: antibiotic therapy, percutaneous catheter drainage or needle aspiration, and open surgery. 6 For many years, antibiotics have been injected i.v. in patients diagnosed with bacterial liver abscess. 4 Nonetheless, the abscess of patients treated with antibiotics takes a considerable period of time to heal.
Moreover, the efficacy of antibiotics varies in each case. Consequently, these patients have to suffer financial constraints under such circumstances. Open surgical procedure is an option for patients who fail to respond positively to antibiotics. It is also carried out in facilities that lack onsite interventional radiology. However, the morbidity and mortality of patients treated with open surgery is significant, 7 thereby limiting the application of this modality. Both image-guided percutaneous catheter drainage (PCD) and needle aspiration are considered to be safe and effective methods in the treatment of pyogenic liver abscess; these methods are recognized as standard methods by many institutions. However, contradictory results have been presented in recent studies that compare the effectiveness of these two methods. 1, 8, 9 Moreover, PCD and needle aspiration are not applicable in the treatment of unliquefied bacterial liver abscess (UBLA). This indicates that antibiotic therapy is the only choice of treatment for patients diagnosed with UBLA.
In our single institutional practice, UBLA is not a rarely seen condition. Since 2011, approximately 17.1% (32/ 187) of patients diagnosed with bacterial liver abscess fell into this category. The typical pathological presentation of UBLA includes degenerative changes in the liver, inflammatory cell infiltration, congestion, and focal liver cell necrosis. In the corresponding sonography reports of these patients, we detected a low-echo mass; its distinction was unclear as it had an irregular boundary and a slightly enhanced peripheral signal. The low-echo mass may transform into an echoless area because of cell necrosis as disease progresses to pyogenic liver abscess. Presently, very few reports have investigated the condition of UBLA. Furthermore, there are no standard guidelines for the treatment of UBLA. Therefore, as well as administering antibiotic therapy to UBLA patients, we also need to urgently develop a novel method that inhibits the progression of this disease.
After carefully considering the challenges associated with the treatment of UBLA, we suggested that ultrasoundguided percutaneous portal vein catheterization must be carried out in the intrahepatic region of UBLA patients. An injection of antibiotics must also be given to these patients. The efficacy of this novel method was subsequently compared with the prognosis of UBLA patients who received only i.v. antibiotic therapy.
MATERIALS AND METHODS

Patients
T HE STUDY PROTOCOL was approved by the Institutional Review Board of Wenzhou Medical College, Zhejiang, China. The inclusion criteria were a white blood cell count >10.0 × 10 9 /L and unliquefied liver abscess in the hypoechoic area; this area had an unclear boundary. A heterogeneous internal echo and blood flow signals had to be detected in an abdominal ultrasound (HI-VISION Avius ultrasound system; Hitachi Medical Corp., Tokyo, Japan). We also included cases presenting a low density area with vague boundary, an enhanced periphery, and a clear inner margin. In computed tomography (LightSpeed VCT 64 Slice CT; GE, Fairfield, CT, USA) of these cases, a vague outer margin was detected after contrast injection. Exclusion criteria were as follows: (i) the routine blood analysis was abnormal (except for white blood cells); (ii) the results of blood coagulation assays were abnormal; (iii) pregnancy; and (iv) major comorbidity. In total, 32 UBLA patients (14 men and 18 women) were enrolled in this study. Among them, 13 patients were recruited from February 2014 to February 2015; these patients were included in an experimental cohort. These patients underwent an ultrasound-guided percutaneous portal vein catheterization in the intrahepatic region then received an injection of antibiotics. The remaining 19 patients were retrospectively enrolled from January 2011 to September 2013; they were included in the control cohort, and they only received i.v. antibiotic therapy. In the experimental cohort, subjects had to observe a fasting period of 8 h before undergoing any medical intervention. All subjects of the experimental group signed an informed consent letter before receiving any medical intervention. All the patients of the control group were retrospectively enrolled; therefore, a written consent letter was waived for this group.
Ultrasound-guided catheterization
The imaging procedure was carried out using a HI-VISION Avius ultrasound system (Hitachi Medical Corp.) equipped with a 2-5 MHz convex probe (EUP-B514). Before catheterization, the size, number, and location of the liver abscess, and the corresponding intrahepatic portal vein were clarified using the ultrasound system (Fig. 1) . The liver abscess was confirmed again to be unliquefied if no abscess cavity or sonolucent area was found, and no pus could be aspirated after an ultrasound-guided puncture under the effect of a local anesthesia. Then, a minimal intubation path was designed and properly marked on the body surface in supine or left lateral position.
The proposed area was sterilized using 0.5% iodophor; a local anesthesia was infiltrated using 4 mL of 2% lidocaine. To undertake catheterization, we used the SKATER Centesis Catheter and Introducer System (PBN Medicals Denmark, Stenlose, Denmark). It contained an 8-Fr catheter, a 16-G puncture needle, and a guidewire. Under the guidance of real-time ultrasound, the puncture needle and catheter were inserted and passed through normal liver tissues until they penetrated through the portal vein. Thereafter, the stylet was taken out, and the venous blood was clearly identified. Subsequently, the guidewire was inserted and the catheter was removed. After successfully expanding the path with a dilatation tube, we placed a guidewire with a 14 G × 20 cm central venous catheterization set with a flex tip (ES-4701; Arrow International, Reading, PA, USA). Finally, the guidewire was removed, and the central venous catheter was connected to a 16 G × 133.35 mm venous indwelling needle (Angiocath; Becton, Dickinson and Company, Franklin Lakes, NJ, USA). Thus, heparin sodium (30 U/mL) injection and antibiotic therapy were given to these patients (Fig. 2) . All ultrasound-guided procedures were carried out by a specialist with 7 years of experience in ultrasonography.
Postoperative management
Cefoperazone and metronidazole were the two antibiotics that were given to all the patients included in this study. This is because no sample of pus was available to carry out a drug sensitivity analysis. Moreover, both Staphylococcus aureus and Escherichia coli, which are the leading causes of bacterial liver abscess, are sensitive to these antibiotics. The experimental group was given cefoperazone (1.5 g, i.v., twice per day) and metronidazole (0.5 g, i.v., twice per day) through a venous indwelling needle. In the control group, the dose of cefoperazone was doubled (3.0 g, peripheral venous, i.v., twice per day); however, the same dosage of metronidazole (0.5 g, i.v., twice per day) was retained. The indwelling needle was removed 3 days after the patients attained a normal body temperature; the abdominal pain of these patients was also relieved. In the follow-up sessions, the subjects underwent routine blood analysis, liver function test, and imaging examinations. The patients were followed for 6 months after receiving medical intervention. In these patients, PCD was carried out if liquefied liver abscess developed after the completion of the treatment.
Statistical analysis
For the experimental and control groups, we recorded the following information: (i) the time elapsed in attaining a normal body temperature; (ii) the time elapsed in attaining normal white blood cell count; (iii) the length of hospitalization; (iv) cases of liquefied liver abscess during follow-up; and (iv) the cost of hospitalization. The numerical data were compared using Student's t-test. The categorical data was analyzed using χ 2 -test. Data were considered to be statistically significant when P < 0.05.
RESULTS
T HE MEAN AGE of enrolled patients was 55 years (range, 32-73 years). All the subjects presented with fever (>38°C), fatigue, and inappetence. Twenty-two patients experienced upper abdominal pain and 25 patients had diabetes mellitus, an underlying disorder. Before initiating the treatment, there were no statistical differences in the two groups for the following parameters: gender, age, clinical presentation, routine blood analysis, and liver function (P > 0.05; Table 1 ).
The catheterization procedure was successfully carried out on all of the patients in the experimental group. Two patients (15.4%) developed complications after undergoing catheterization. One patient developed slight internal bleeding, whereas the other patient developed Portal
sudden catheter blockage; however, both complications were resolved by non-surgical procedures. Thus, even these two patients successfully underwent all treatments. During the follow-up, we did not come across any case of internal bleeding, bile leakage, or thrombosis. Further surgical treatment was not required by any of the patients during follow-up.
Compared to the control group, the experimental group showed faster recovery. Compared to the control group, the experimental group recorded significantly shorter/lower parameters for the following events: (i) the time required for attaining normal body temperature; (ii) the time required for attaining normal white blood cell count; (iii) the length of hospitalization; (iv) cases of liquefied liver abscess during follow-up; and (v) cost of hospitalization (all P < 0.05; Fig. 1, Table 2 ). Moreover, levels of alanine amino transferase, aspartate aminotransferase, and lactate dehydrogenase returned to normal (35.1 ± 9.4 U/L, 39.5 ± 7.5 U/L, and 157 ± 31.1 U/L, respectively) in patients subjected to intraportal antibiotic therapy. Thus, this strategy significantly inhibited inflammation; however, it induced minor injury to liver cells.
DISCUSSION
I
N THIS WORK, our data established that when ultrasound-guided percutaneous portal vein catheterization was carried out in the intrahepatic region of patients injected with antibiotics, the results were much better than those witnessed in patients treated with only systemic antibiotic therapy. Compared to the control group, a shorter duration of time was required by the experimental subjects to regain normal body temperature and normal white blood cell count. Therefore, the length of hospitalization was successfully shortened in the experimental group. The rate of recurrence of liver abscess was also lower in the experimental group. Moreover, the cost of treatment was significantly lower for the experimental group. These results confirm that when an injection of antibiotics is given through the intrahepatic portal vein, the efficacy of medication increases. Thus, the prognosis of the treatment occurs in a relatively short period of time. Therefore, this method is a better choice for patients with UBLA.
In past decades, PCD and antibiotics have been the standard treatments for patients with bacterial liver abscess. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Moreover, PCD is a safe, effective, and simple option for those who develop pyogenic liver abscess. In particular, PCD is the preferred mode of treatment in patients diagnosed with large abscess (>10 cm). 12 Previous research studies reported that the postsurgical morbidity and complications of PCD are lower than those of 19 Moreover, PCD is better than percutaneous needle aspiration, because the former has a relatively higher success rate. It also provides clinical relief in a relatively shorter duration of time. 20, 21 However, not all cases of bacterial liver abscess can be effectively treated with PCD. In clinical practice, UBLA is one of the most common cases that cannot be cured by PCD, because no abscess cavity is formed in patients with UBLA and the abscess cannot be drained out. In such circumstances, an i.v. antibiotic therapy is prescribed to patients with UBLA. Nonetheless, a systemic treatment has to be provided for a relatively longer duration of time, because antibiotics require some time to attain a high concentration in liver. Surgical procedures and systemic therapy are expensive. 19 Moreover, there are many chances of complications in these procedures, and the clinical outcome is also uncertain. Therefore, the application of these two methods is quite limited. In this study, we proposed that percutaneous portal vein catheterization should be carried out in the intrahepatic region of patients and an injection of antibiotics must also be given to these patients. Such a novel strategy served as an excellent solution for patients with UBLA. This minimally invasive procedure showed promising results. As drugs were directly introduced into the portal vein, a high concentration of antibiotics was easily attained in the liver. Thus, the efficacy of this novel treatment was much higher than that of conventional methods.
According to our novel experiences in this study, it is advisable to undertake ultrasound-guided percutaneous portal vein catheterization in the intrahepatic region of UBLA patients; an injection of antibiotics must also be given to these patients. Ultrasound guidance is more convenient and safer than computed tomography, because it requires less procedure time. Moreover, it can be easily performed on wards, and we can also prevent patients from being exposed to unnecessary radiation. Patients can also adjust their position at any point of time during the surgery. Thus, we can obtain better images of various catheterization paths. Real-time surveillance helps to reduce the potential risk of damage in major organs/arteries and minimizes the possibility of internal bleeding and drug leakage. Furthermore, the efficacy of this treatment can be determined promptly. Finally, the total dose of antibiotics can be significantly reduced, provided the drugs are concentrated in the liver. With an increase in efficacy, the cost and duration of hospitalization are remarkably reduced.
Nonetheless, this new technique has some limitations. Internal bleeding and catheter blockage are inevitable. These complications may lead to fatal events if not handled properly. However, we only came across cases with slight internal bleeding and partial catheter blockage; both of these complications were successfully managed with non-surgical treatments. This indicates that a comprehensive postoperative management is essential for tackling the complications of this technique. Moreover, ultrasound alone is not quite sensitive enough to distinguish UBLA from hepatocarcinoma in equivocal cases. Therefore, we suggest that contrast-enhanced ultrasonography and magnetic resonance imaging must also be carried out in future studies. Finally, our exploratory work only included cases with a single lesion. In the near future, research studies will be undertaken to investigate whether cauterization can be carried out in the main portal vein to manage multiple liver abscesses.
CONCLUSION
I N SUMMARY, ULTRASOUND-GUIDED percutaneous portal vein catheterization must be carried out in the intrahepatic region of UBLA patients, and an injection of antibiotics should also be given. This is a simple, minimally invasive, and effective treatment for UBLA. However, it can only be used in selected cases.
